
NASA's Next-Gen Rocket Booster Explodes in Test of a Design That May Never Fly
On Thursday in Utah, Northrop Grumman conducted the first full-scale static fire test of the newly built solid rocket booster. NASA's Booster Obsolescence and Life Extension (BOLE) is the 'world's largest and most powerful segmented solid rocket motor,' according to Northrop Grumman. The test lasted for a little over two minutes, burning more than 1.4 million pounds of propellant. Toward the end, however, an unusually bright plume appeared to suddenly burn through parts of the booster, resulting in a large fireball and flying debris. In the video (shown below), the anomaly appears at the 22:15 mark.
'Today's test pushed the boundaries of large solid rocket motor design to meet rigorous performance requirements,' Jim Kalberer, vice president of propulsion systems at Northrop Grumman, said in a statement. 'While the motor appeared to perform well through the most harsh environments of the test, we observed an anomaly near the end of the two-plus minute burn.'
The anomaly was likely caused by a faulty nozzle on the booster. 'The nozzle liberated energetically from the motor around 10 seconds before the burn ended, and there appeared to be some debris leaving the nozzle just before the main disintegration of the nozzle happened,' NASA Spaceflight reports.
Northrop Grumman developed the new booster under a $3.2 billion contract with NASA. The booster features carbon-fiber composite cases, which are meant to be lighter and stronger than the shuttle-era steel cases currently on SLS. Instead of the SLS booster's current hydraulic thrust vector control steering system, BOLE uses an electronic system. It also uses a different propellant formula that's meant to increase performance by around 10% and adds another five metric tons of payload.
NASA's massive, fully expendable Moon rocket is under heavy scrutiny. The 5.75-million-pound SLS was built using components from NASA's Space Shuttle program, which ran from 1981 to 2011. SLS is outfitted with four RS-25 engines originally built by Aerojet Rocketdyne for the shuttle project. NASA has a total of four contracts with Aerojet Rocketdyne for the RS-25 engines and Northrop Grumman for the boosters, which were also used during the Shuttle era, before the space agency switches to the newly designed BOLE. The new booster is intended for use on SLS beginning with Artemis 9, which is currently scheduled for 2034.
SLS is a capable heavy-lift rocket, but it's ultimately unaffordable. The launch vehicle has already gone $6 billion over budget, with the projected cost of each SLS rocket being $144 million more than anticipated. That would increase the overall cost of a single Artemis launch to at least $4.2 billion, according to a report released in 2024 by the office of NASA's inspector general. In its budget proposal for 2026, the U.S. administration laid out a plan to phase out SLS and its Orion capsule, replacing them with commercial substitutes. To be clear, SLS is not officially dead, but it doesn't look good.
Despite the uncertainty surrounding SLS, NASA carried out another test of the rocket's components last week. On June 20, the agency tested an RS-25 engine at the Fred Haise Test Stand at NASA's Stennis Space Center in Mississippi. This was the first hot fire test of the new RS-25 engines, and it lasted around eight and a half minutes or 'the same amount of time RS-25 engines fire during a launch of an SLS rocket on Artemis missions to the Moon,' according to NASA.
NASA seems to be making progress with the new designs for its SLS rocket, but it's not clear whether these new parts will get to launch a mission to the Moon.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Biodesix Recognized as a Thermo Fisher Scientific Center of Excellence (COE) for NGS Diagnostics
Biodesix recently validated Thermo Fisher's tissue-based Oncomine Dx Express Test for solid tumors on the Genexus Dx Integrated Sequencer LOUISVILLE, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leader in personalized diagnostics, announced that the company is designated as a Thermo Fisher Scientific Center of Excellence (COE) as part of Thermo Fisher's collaborative initiative to advance NGS-based diagnostics. The services provided to Thermo Fisher are an example of Biodesix Development Services offerings, including customizable options that enable the world's leading life sciences companies, biopharmaceutical, and medical research institutions with scientific, technological, and operational capabilities. As Thermo Fisher announced in July 2025, Biodesix was an instrumental partner in the validation of the Oncomine Dx Express Test leading to the FDA approval of the Genexus Dx Integrated Sequencer. Biodesix Development Services conducted validation studies utilizing its design-controlled laboratory processes, quality management systems, and contributed data generation in support of regulatory submission. 'Working with Thermo Fisher, we continue to forge a path to conquer cancer, and we are delighted to expand our molecular diagnostic and NGS testing capabilities in tissue-based profiling,' said Scott Hutton, CEO at Biodesix. "Being a member of Thermo Fisher's COE network puts us in excellent company with other global groups committed to transforming cancer diagnosis and care. We are excited about the potential to offer the Oncomine Dx Express Test in the future.' Upcoming presentations to learn more about the Thermo Fisher NGS precision oncology solution and how Biodesix will apply the science for its industry clients and healthcare professionals: August 27, 2025 | CAP TODAY | Thermo Fisher Scientific Webinar: Introduction of new FDA approved rapid NGS solution for Companion Diagnostics & tumor profiling in oncology. Speakers: David Chi, PhD, Thermo Fisher Scientific, Bence Sipos, MD, and Gary Pestano, PhD, Chief Development Officer, Biodesix September 15, 2025 | Orlando, FL | College of American Pathologists (CAP) 2025 Annual Meeting | Thermo Fisher-sponsored Panel: "Introduction of new IVD solution for rapid NGS profiling in Oncology". Speakers: Mahmoud Elsayad, MD, FCAP, University of Texas Health, Alison Roos, Thermo Fisher Scientific, and Gary Pestano, PhD, Chief Development Officer, Biodesix About Biodesix:Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world's leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit About the Thermo Fisher COE Network: Thermo Fisher's NGS COE Network partners with leading global institutions to develop, validate, and refine its Ion Torrent™ Oncomine™ solutions portfolio. Through these COEs, Thermo Fisher collaborates with experts to accelerate oncology research, foster strategic alliances, and advance precision medicine. Biodesix Contacts: Media:Natalie St. Denis, Director Corporate Communications, 925-9285 Investors:Chris Brinzey, Partner, 970-2843
Yahoo
19 minutes ago
- Yahoo
Traumatic brain injuries linked to faster aging in post-9/11 veterans, new study finds
New research published in the Journal of Head Trauma Rehabilitation could help identify veterans at risk for health problems Research Highlights: More than half of post-9/11 veterans studied had suffered at least one traumatic brain injury (TBI) and showed faster biological aging. TBIs sustained during military deployment showed stronger links to accelerated aging compared to injuries outside military service. Compared to men, women veterans showed significantly stronger links between deployment-related TBIs and accelerated aging. FAIRFAX, Va., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Post 9/11 veterans who sustained one or more traumatic brain injuries show faster biological aging compared to veterans without a TBI, according to new research published today in the Journal of Head Trauma Rehabilitation. In more than 1,000 veterans studied, deployment-related traumatic brain injuries had stronger links to accelerated aging than injuries outside military service, particularly among women. More recent injuries also showed stronger associations with aging than injuries prior to military service. 'This is one of the first studies to examine whether traumatic brain injury is associated with biological aging broadly, and the results suggest experiencing a TBI, including a mild concussion, may help identify veterans at risk of faster aging,' says lead author Kyle Bourassa, Ph.D., staff psychologist in Research Service at the Durham Veterans Affairs Health Care System and senior research fellow in the Department of Psychology at Georgetown University. Nearly 5 million Americans have served in the armed forces since September 11, 2001, participating in combat operations in Iraq and Afghanistan. This post-9/11 population faces increased risks for traumatic brain injuries, psychiatric disorders and suicide, compared to earlier generations of veterans. Research has shown that brain injury can evolve into a lifelong health condition that impairs the brain and other organ systems and may persist or progress over a person's lifetime. Previous research has linked TBI to poor brain health in the form of cognitive decline and dementia risks, but scientists still aim to understand why these problems develop. The new study examined whether accelerated biological aging could help explain these health consequences. Biological aging measures the rate at which a person's body declines over time, but some people age biologically faster than others. Researchers used blood samples to assess aging markers that predict future health problems, including chronic disease and early death. The findings suggest TBIs, particularly those sustained during deployment, may put veterans at a higher risk for age-related health complications as they grow older. Researchers conducted a cross-sectional study analyzing blood samples from 1,152 post-9/11 veterans with an average age of 37 years enrolled in a long-term study with the Veterans Affairs VISN 6 Mid-Atlantic Mental Illness research, Education and Clinical Center. In this multi-site study, participants underwent clinical interviews about their history of traumatic brain injuries, including when and how the injuries occurred. Scientists used blood samples to measure epigenetic changes – chemical modifications to DNA that respond to environmental factors – to assess biological aging rates. Unlike permanent genetic traits, these epigenetic changes can be influenced by factors like injuries or stress, making them potentially reversible. The aging measure, called DunedinPACE, predicts future health outcomes. Key Findings TBI prevalence: More than half (51.2%) of the 1,152 veterans studied experienced at least one traumatic brain injury, with 299 reporting multiple injuries. Deployment-related injuries: Among the 590 veterans with TBI, more than one in four (27.3%) sustained an injury during military deployment. Co-occurring conditions: Nearly one-third of all participants (31.6%) had received a post-traumatic stress disorder diagnosis, and veterans with multiple TBIs were more likely to have developed PTSD. Deployment vs. non-deployment associations: Deployment-related TBIs were associated with accelerated aging, whereas traumatic brain injuries experienced outside of military service were not. Gender differences: Women veterans showed significantly stronger links between deployment-related TBIs and accelerated aging compared to men. Bourassa believes the findings could help identify approaches to improve health for people with a traumatic brain injury saying, 'We know more work is needed, but our findings highlight the importance of integrating TBI screenings and tailored interventions into veteran health care frameworks, which could help address the long-term health consequences associated with military service-related brain injuries.' 'This study provides further evidence that TBI can be a risk factor for abnormal aging, but what is important is what we can do about it,' observed John Corrigan, Ph.D., National Research Director for the Brain Injury Association of America (BIAA) and editor-in-chief of the Journal for Head Trauma Rehabilitation. 'Having a TBI should be a reason to take better care of your brain through diet, exercise, sleep, stress management and other brain healthy behaviors. BIAA promotes identification of TBI with programs like Concussion Awareness Now, so people can learn the signs and symptoms of a concussion and ways to make healthy choices moving forward.' Scientists noted several important limitations to the research. Because it was a cross-sectional study, the findings cannot prove that TBI caused faster aging, only that the two are linked. Additionally, researchers assessed a participant's TBI history through self-reported clinical interviews, which can be subject to recall bias. Bourassa noted their study team is conducting a new study using a more detailed method of assessing TBI to attempt to address this limitation. The study also focused on post-9/11 veterans, which may limit how the findings apply to other veteran populations or civilians with traumatic brain injuries. Future studies should examine whether the findings can be replicated in other groups and explore what biological processes lead to accelerated aging following a TBI. Scientists also need to better understand why deployment-related injuries might show stronger associations with aging for women veterans. Co-authors are Sarah L. Martindale, Ph.D.; Melanie E. Garret, M.S.; VA Mid-Atlantic MIRECC Workgroup; Allison E. Ashley-Koch; Jean C. Beckham, Nathan A. Kimbrel, Jared A. Rowland; Ph.D. Financial disclosures or conflicts of interest can be found in the full article. ABOUT THE BRAIN INJURY ASSOCIATION OF AMERICA The Brain Injury Association of America is the country's oldest and largest nationwide brain injury advocacy organization. BIAA's mission is to improve the quality of life of people affected by brain injury across their lifespan through advancing prevention, awareness, research, treatment, education, and advocacy. BIAA is dedicated to increasing access to quality health care and raising awareness and understanding of brain injury. Find more information online at our website or follow us on social media. CONTACT: CONTACT: Robin Lindner (336) 926-8000 robin@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


New York Times
21 minutes ago
- New York Times
Is Extreme Running Linked to Colon Cancer?
The three patients should have been portraits of health. They were young, lean and physically active. Unusually active, in fact: Two regularly ran 100-mile ultramarathons, and one had completed 13 half-marathons in a single year. By the time they came to see Dr. Timothy Cannon, all three had advanced colon cancer. He was mystified; the oldest of them was 40, and none had any known risk factors. The doctor couldn't help wondering if extreme running might have played a role. So Dr. Cannon, an oncologist with Inova Schar Cancer in Fairfax, Va., launched a study, recruiting 100 marathon and ultramarathon runners aged 35 to 50 to undergo a colonoscopy. The results were staggering. Almost half the participants had polyps, and 15 percent had advanced adenomas likely to become cancerous. The rate of advanced adenomas was much higher than that seen among adults in their late 40s in the general population, which ranges from 4.5 percent to 6 percent, according to recent studies The figure among extreme runners was even higher than the 12 percent rate among Alaska Natives, who are unusually prone to colon cancer. The research was presented at an American Society of Clinical Oncology conference but has not yet been published in a medical journal. Want all of The Times? Subscribe.